

Petronella B Ottevanger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1537470/publications.pdf>

Version: 2024-02-01

134
papers

6,652
citations

101543

36
h-index

69250

77
g-index

134
all docs

134
docs citations

134
times ranked

8909
citing authors

#	ARTICLE	IF	CITATIONS
1	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1274-1284.	10.7	1,376
2	Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. <i>Annals of Oncology</i> , 2019, 30, 1080-1087.	1.2	456
3	Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 295-309.	10.7	426
4	Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1273-1285.	10.7	305
5	Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. <i>Lancet Oncology</i> , The, 2012, 13, 256-264.	10.7	237
6	Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. <i>Lancet Oncology</i> , The, 2018, 19, 337-346.	10.7	235
7	Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 78-89.	10.7	205
8	Gynecologic Cancers in Pregnancy: Guidelines of a Second International Consensus Meeting. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 394-403.	2.5	198
9	Angiotensin II Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1030.	7.1	160
10	BREATH: Web-Based Self-Management for Psychological Adjustment After Primary Breast Cancer—Results of a Multicenter Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2763-2771.	1.6	153
11	Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1114-1126.	10.7	135
12	Ovarian cancer stem cells more questions than answers. <i>Seminars in Cancer Biology</i> , 2017, 44, 67-71.	9.6	128
13	Lung cancer in pregnancy: Report of nine cases from an international collaborative study. <i>Lung Cancer</i> , 2013, 82, 499-505.	2.0	107
14	Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	83
15	Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. <i>Gynecologic Oncology</i> , 2012, 125, 576-579.	1.4	79
16	Distress screening remains important during follow-up after primary breast cancer treatment. <i>Supportive Care in Cancer</i> , 2013, 21, 2107-2115.	2.2	71
17	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 862-876.	10.7	68
18	Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage lb2-IIb cervical cancer, EORTC 55994.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5503-5503.	1.6	68

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review. <i>Lancet Oncology</i> , The, 2011, 12, 1053-1061.	10.7	66
20	Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3324-3330.	1.6	61
21	Quality assurance for radical hysterectomy for cervical cancer: the view of the European Organization for Research and Treatment of Cancerâ€™Gynecological Cancer Group (EORTC-GCG). <i>Annals of Oncology</i> , 2009, 20, 1631-1638.	1.2	60
22	Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNAâ€™Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). <i>Journal of Clinical Oncology</i> , 2016, 34, 2516-2525.	1.6	60
23	Development of Generic Quality Indicators for Patient-Centered Cancer Care by Using a RAND Modified Delphi Method. <i>Cancer Nursing</i> , 2012, 35, 29-37.	1.5	59
24	Primary brain tumours, meningiomas and brain metastases in pregnancy: Report on 27 cases and review of literature. <i>European Journal of Cancer</i> , 2014, 50, 1462-1471.	2.8	54
25	Radiation therapy combined with hyperthermia versus cisplatin for locally advanced cervical cancer: Results of the randomized RADCHOC trial. <i>Radiotherapy and Oncology</i> , 2016, 120, 378-382.	0.6	54
26	Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands. <i>Acta OncolÃ³gica</i> , 2013, 52, 950-955.	1.8	51
27	Trends in incidence for gestational trophoblastic disease over the last 20years in a population-based study. <i>Gynecologic Oncology</i> , 2016, 140, 70-75.	1.4	49
28	EORTCâ€™GCG process quality indicators for ovarian cancer surgery. <i>European Journal of Cancer</i> , 2009, 45, 517-526.	2.8	48
29	Systemic review: Radiation therapy alone in medical non-operable endometrial carcinoma. <i>European Journal of Cancer</i> , 2016, 65, 172-181.	2.8	48
30	Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study. <i>Lancet Haematology</i> , the, 2019, 6, e551-e561.	4.6	45
31	Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5511-5511.	1.6	45
32	Systemic treatment in adult uterine sarcomas. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 10-20.	4.4	44
33	Rationale of the BREast cancer e-heALTH [BREATH] multicentre randomised controlled trial: An Internet-based self-management intervention to foster adjustment after curative breast cancer by decreasing distress and increasing empowerment. <i>BMC Cancer</i> , 2012, 12, 394.	2.6	42
34	Final results from GCIG/ENGOT/AGOâ€™COVAR 12, a randomised placeboâ€™controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. <i>International Journal of Cancer</i> , 2020, 146, 439-448.	5.1	40
35	Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer. <i>JAMA Network Open</i> , 2020, 3, e1918939.	5.9	40
36	Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer. <i>Anti-Cancer Drugs</i> , 2010, 21, 749-758.	1.4	38

#	ARTICLE	IF	CITATIONS
37	The Cancer Empowerment Questionnaire: Psychological Empowerment in Breast Cancer Survivors. <i>Journal of Psychosocial Oncology</i> , 2013, 31, 565-583.	1.2	38
38	Effect of a Skills Training for Oncologists and a Patient Communication Aid on Shared Decision Making About Palliative Systemic Treatment: A Randomized Clinical Trial. <i>Oncologist</i> , 2020, 25, e578-e588.	3.7	37
39	Training for Medical Oncologists on Shared Decision-Making About Palliative Chemotherapy: A Randomized Controlled Trial. <i>Oncologist</i> , 2019, 24, 259-265.	3.7	36
40	Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data. <i>European Journal of Endocrinology</i> , 2020, 182, 131-138.	3.7	36
41	Quality of pathology reports for advanced ovarian cancer: Are we missing essential information?. <i>European Journal of Cancer</i> , 2011, 47, 57-64.	2.8	34
42	Development and Measurement of Guideline-Based Indicators for Patients With Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1436-1444.	1.6	34
43	Arthralgia During Aromatase Inhibitor Treatment in Early Breast Cancer Patients. <i>Cancer Nursing</i> , 2013, 36, 52-59.	1.5	33
44	Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer. <i>European Journal of Cancer</i> , 2014, 50, 2592-2601.	2.8	33
45	The prognostic value of WHO performance status in relation to quality of life in advanced colorectal cancer patients. <i>European Journal of Cancer</i> , 2016, 66, 138-143.	2.8	33
46	A Specific Distress Cutoff Score Shortly After Breast Cancer Diagnosis. <i>Cancer Nursing</i> , 2017, 40, E35-E40.	1.5	33
47	Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy. <i>European Journal of Cancer</i> , 2020, 138, 57-67.	2.8	31
48	Implementing physical activity programs for patients with cancer in current practice: patients' experienced barriers and facilitators. <i>Journal of Cancer Survivorship</i> , 2019, 13, 703-712.	2.9	29
49	Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia. <i>European Journal of Cancer</i> , 2013, 49, 860-867.	2.8	28
50	Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT. <i>Targeted Oncology</i> , 2014, 9, 339-347.	3.6	28
51	Association of Chemotherapy Timing in Pregnancy With Congenital Malformation. <i>JAMA Network Open</i> , 2021, 4, e2113180.	5.9	27
52	Fatal cases of gestational trophoblastic neoplasia over four decades in the Netherlands: a retrospective cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2012, 119, 1465-1472.	2.3	25
53	Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6005-6005.	1.6	25
54	Quality assurance in clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 47, 213-235.	4.4	23

#	ARTICLE	IF	CITATIONS
55	The added value of hysterectomy in the management of gestational trophoblastic neoplasia. <i>Gynecologic Oncology</i> , 2017, 145, 536-542.	1.4	23
56	Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5502-5502.	1.6	23
57	Self-Reported Distress in Patients With Ovarian Cancer: Is It Related to Disease Status?. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 229-235.	2.5	22
58	Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based study. <i>European Journal of Cancer</i> , 2020, 133, 104-111.	2.8	22
59	Can the FIGO 2000 scoring system for gestational trophoblastic neoplasia be simplified? A new retrospective analysis from a nationwide dataset. <i>Annals of Oncology</i> , 2017, 28, 1856-1861.	1.2	21
60	Neoadjuvant Chemotherapy Followed by Vaginal Radical Trachelectomy as Fertility-Preserving Treatment for Patients with FIGO 2018 Stage 1B2 Cervical Cancer. <i>Oncologist</i> , 2020, 25, e1051-e1059.	3.7	21
61	Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol. <i>BMJ Open</i> , 2021, 11, e050725.	1.9	21
62	Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase Tj ETQq0 0 0,rgBT /Overlock 10 TF	1.4	19
63	Assessing the information desire of patients with advanced cancer by providing information with a decision aid, which is evaluated in a randomized trial: a study protocol. <i>BMC Medical Informatics and Decision Making</i> , 2011, 11, 9.	3.0	18
64	Gastric cancer during pregnancy: A report on 13 cases and review of the literature with focus on chemotherapy during pregnancy. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2020, 99, 79-88.	2.8	18
65	Healthcare professionals's perspectives of barriers and facilitators in implementing physical activity programmes delivered to cancer survivors in a shared-care model: a qualitative study. <i>Supportive Care in Cancer</i> , 2020, 28, 3429-3440.	2.2	18
66	Linear Regression of Postevacuation Serum Human Chorionic Gonadotropin Concentrations Predicts Postmolar Gestational Trophoblastic Neoplasia. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 1151-1157.	2.5	17
67	Patients's Preferences for Information About the Benefits and Risks of Second-Line Palliative Chemotherapy and Their Oncologist's Awareness of These Preferences. <i>Journal of Cancer Education</i> , 2016, 31, 443-448.	1.3	17
68	Adherence to the guidelines of the CCCE in the treatment of node-positive breast cancer patients. <i>European Journal of Cancer</i> , 2004, 40, 198-204.	2.8	16
69	Efficacy of a Regional Network for Ovarian Cancer Care. <i>Obstetrics and Gynecology</i> , 2013, 122, 668-675.	2.4	16
70	The Impact of the Extent of Surgery on the Long-Term Outcomes of Patients with Low-Risk Differentiated Non-Medullary Thyroid Cancer: A Systematic Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2316.	2.4	16
71	Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®). <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 457-463.	2.3	15
72	Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP). <i>Clinical Pharmacokinetics</i> , 2021, 60, 775-784.	3.5	15

#	ARTICLE	IF	CITATIONS
73	Review: Effectiveness of implementation strategies to increase physical activity uptake during and after cancer treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 157-163.	4.4	14
74	Maternal and neonatal outcomes in 80 patients diagnosed with non-Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy. <i>British Journal of Haematology</i> , 2021, 193, 52-62.	2.5	14
75	Psychometric properties of the 45-item supportive care needs survey"partners and caregivers - Dutch (SCNS-P&C45-D) in partners of patients with breast cancer. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 1.	1.9	13
76	CD34 progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rg null mice. <i>Oncolmmunology</i> , 2021, 10, 1981049.	4.6	13
77	Decision aids for second-line palliative chemotherapy: a randomised phase II multicentre trial. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 130.	3.0	12
78	Effects of quality of treatment on prognosis in primary breast cancer patients treated in daily practice. <i>Anticancer Research</i> , 2002, 22, 459-65.	1.1	12
79	Possibilities for transborder cooperation in breast cancer care in Europe: A comparative analysis regarding the content, quality and evidence use of breast cancer guidelines. <i>Breast</i> , 2008, 17, 464-471.	2.2	11
80	Surgical program building in advanced ovarian cancer: European perspective. <i>Gynecologic Oncology</i> , 2009, 114, S10-S14.	1.4	11
81	Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1141-1147.	2.5	11
82	The quality of chemotherapy and its quality assurance. <i>European Journal of Surgical Oncology</i> , 2005, 31, 656-666.	1.0	10
83	The effectiveness of a nurse-led intervention with the distress thermometer for patients treated with curative intent for breast cancer: design of a randomized controlled trial. <i>BMC Cancer</i> , 2016, 16, 520.	2.6	10
84	Dutch Risk Classification and FIGO 2000 for Gestational Trophoblastic Neoplasia Compared. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1712-1716.	2.5	10
85	Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. <i>Gynecologic Oncology</i> , 2019, 152, 235-242.	1.4	10
86	Does a regular nurse-led distress screening and discussion improve quality of life of breast cancer patients treated with curative intent? A randomized controlled trial. <i>Psycho-Oncology</i> , 2020, 29, 719-728.	2.3	10
87	Quality of adjuvant chemotherapy in primary breast cancer in a non-trial setting. A comprehensive cancer centre study. <i>European Journal of Cancer</i> , 1999, 35, 386-391.	2.8	9
88	A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer. <i>Annals of Oncology</i> , 2010, 21, 415-418.	1.2	9
89	Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 1139-1145.	2.3	9
90	The psychological impact of gestational trophoblastic disease: a prospective observational multicentre cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 444-449.	2.3	9

#	ARTICLE	IF	CITATIONS
91	Determinants of adherence to physical cancer rehabilitation guidelines among cancer patients and cancer centers: a cross-sectional observational study. <i>Journal of Cancer Survivorship</i> , 2021, 15, 163-177.	2.9	9
92	Development and Evaluation of an Educational E-Tool to Help Patients With Non-Hodgkin's Lymphoma Manage Their Personal Care Pathway. <i>JMIR Research Protocols</i> , 2015, 4, e6.	1.0	9
93	Serum Human Chorionic Gonadotropin Normogram for the Detection of Gestational Trophoblastic Neoplasia. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1035-1041.	2.5	8
94	Presence of gastro-intestinal symptoms in ovarian cancer patients during survivorship: a cross-sectional study from the PROFILES registry. <i>Supportive Care in Cancer</i> , 2019, 27, 2285-2293.	2.2	8
95	Delivering high-quality care to patients with a non-Hodgkin's lymphoma: barriers perceived by patients and physicians. <i>Netherlands Journal of Medicine</i> , 2014, 72, 41-8.	0.5	8
96	Expected survival with and without second-line palliative chemotherapy: who wants to know?. <i>Health Expectations</i> , 2015, 18, 2903-2914.	2.6	7
97	Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy. <i>Clinical and Translational Oncology</i> , 2019, 21, 774-780.	2.4	7
98	Human chorionic gonadotropin (hCG) regression normograms for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D.) <i>Tj ETQqO 0 0 rgBT /Overlor 12 10 Tf 50 457 Td (</i>	2.6	7
99	Variation in guideline adherence in non-Hodgkin's lymphoma care: impact of patient and hospital characteristics. <i>BMC Cancer</i> , 2015, 15, 578.	2.6	6
100	An impressive response to pazopanib in a patient with metastatic endometrial carcinoma. <i>Netherlands Journal of Medicine</i> , 2016, 74, 410-413.	0.5	6
101	Encouraging results in older patients receiving chemotherapy: A retrospective analysis of treatment guideline adherence in daily practice. <i>Geriatrics and Gerontology International</i> , 2012, 12, 80-85.	1.5	5
102	The role of surgery in the management of patients with platinum-sensitive recurrent ovarian cancer: Survey among Dutch gynecologists and medical oncologists. <i>Gynecologic Oncology</i> , 2013, 131, 561-566.	1.4	5
103	Study protocol: an evaluation of the effectiveness, experiences and costs of a patient-directed strategy compared with a multi-faceted strategy to implement physical cancer rehabilitation programmes for cancer survivors in a European healthcare system; a controlled before and after study. <i>Implementation Science</i> , 2015, 10, 128.	6.9	5
104	Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5505-5505.	1.6	5
105	Distinct Genomic Profiles Are Associated with Treatment Response and Survival in Ovarian Cancer. <i>Cancers</i> , 2022, 14, 1511.	3.7	5
106	Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 898-905.	2.5	4
107	Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 223, 98-102.	1.1	4
108	Localization of distant metastases defines prognosis and treatment efficacy in patients with FIGO stage IV ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 392-397.	2.5	4

#	ARTICLE	IF	CITATIONS
109	High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 536700.	2.8	4
110	Data describing child development at 6 years after maternal cancer diagnosis and treatment during pregnancy. <i>Data in Brief</i> , 2020, 32, 106209.	1.0	4
111	Immune cell composition in the endometrium of patients with a complete molar pregnancy: Effects on outcome. <i>Gynecologic Oncology</i> , 2021, 160, 450-456.	1.4	4
112	Correlation between strength of T-cell response against HPV16 and survival after vaccination with HPV16 long peptides in combination with chemotherapy for late-stage cervical cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 140-140.	1.6	4
113	Improvement of hospital care for patients with non-Hodgkinâ€™s lymphoma: protocol for a cluster randomized controlled trial (PEARL study). <i>Implementation Science</i> , 2013, 8, 77.	6.9	3
114	Exploring the Routine Administration of Decision Aids for Palliative Chemotherapy to Patients by Nurses. <i>Cancer Nursing</i> , 2015, 38, 270-278.	1.5	3
115	Trends in quality of non-Hodgkinâ€™s lymphoma care: is it getting better?. <i>Annals of Hematology</i> , 2015, 94, 1195-1203.	1.8	3
116	Needs, Preferences, and Values during Different Treatment Decisions of Patients with Differentiated Thyroid Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 682.	2.5	3
117	PENELOPE/AGO-OVAR 2.20: A double-blind placebo (PLA)-controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum-resistant ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS5613-TPS5613.	1.6	3
118	Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5504-5504.	1.6	3
119	Authorsâ€™ response re: The psychological impact of gestational trophoblastic disease: a prospective observational multicentre cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 833-834.	2.3	3
120	TSH-dependent production of T4 and T3 by metastases of a thyroid carcinoma. <i>European Journal of Endocrinology</i> , 1992, 127, 413-415.	3.7	2
121	Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement. <i>Gynecologic Oncology</i> , 2021, 163, 531-537.	1.4	2
122	Independent review of AGO-OVAR 12, a GCIG/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5556-5556.	1.6	2
123	Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5501-5501.	1.6	2
124	Centralised registration of gestational trophoblastic disease and trends in incidence. <i>Acta Oncologica</i> , 2012, 51, 415-416.	1.8	1
125	Evaluation of two strategies to implement physical cancer rehabilitation guidelines for survivors of abdominopelvic cavity tumors: a controlled before-and-after study. <i>Journal of Cancer Survivorship</i> , 2022, 16, 497-513.	2.9	1
126	A phase Ib study of the combination of temsirolimus (T) and pegylated liposomal doxorubicin (PLD) in advanced or recurrent breast, endometrial, and ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5061-5061.	1.6	1

#	ARTICLE	IF	CITATIONS
127	The prognostic value of tumor residuals indicated by surgeon, by radiology or an integrated approach by surgeons' assessment and pre-chemotherapy CT-scan in patients with advanced ovarian cancer: An exploratory analysis of the AGO Study led Intergroup trial AGO-OVAR 12.. Journal of Clinical Oncology, 2017, 35, 5521-5521.	1.6	1
128	RE: Generalizability of Trial Results to Elderly Medicare Patients With Advanced Solid Tumors. Journal of the National Cancer Institute, 2015, 107, djv104-djv104.	6.3	0
129	Development of quality indicators for non-Hodgkin lymphoma. Journal of Clinical Oncology, 2007, 25, 17017-17017.	1.6	0
130	Patient information desire in actual decision making for advanced cancer treatment: Do doctors know their patients?. Journal of Clinical Oncology, 2012, 30, 9036-9036.	1.6	0
131	A randomized trial of a nurse-led decision aid to inform patients with advanced cancer about palliative chemotherapy.. Journal of Clinical Oncology, 2013, 31, e20583-e20583.	1.6	0
132	Pertuzumab (P) plus chemotherapy (CT) for platinum-resistant ovarian cancer: Safety run-in results of the PENELOPE trial.. Journal of Clinical Oncology, 2014, 32, 5552-5552.	1.6	0
133	Improving hospital care for patients with non-Hodgkin's lymphomas.. Journal of Clinical Oncology, 2016, 34, 6593-6593.	1.6	0
134	Progression free survival (PFS) as a surrogate endpoint for overall survival (OS) in first-line advanced ovarian cancer (AOC) therapy: A Gynecologic Cancer InterGroup individual (GCIG) patient-level (IPD) analysis of multiple randomized trials.. Journal of Clinical Oncology, 2018, 36, 5576-5576.	1.6	0